Alvotech has now entered four biosimilar candidates into confirmatory patient studiesCombined sales of Prolia® and Xgeva® (denosumab) which are used to treat bone diseases were nearly $5.3...

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team...

On 15 August 2022, Alvotech filed a Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission, with regards to the indemnification of Alvotech’s directors and officers.

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results...

After becoming the first Icelandic company to list its shares both in the U.S. and Iceland, Alvotech prepares to move to the Nasdaq Main Market in IcelandListing on the Main Market can increase...

On 27 July 2022, Alvotech filed an amendment to the Registration Statement on Form F-1 (the “Preliminary Prospectus”), previously filed on July 14 2022, with the U.S. Securities and Exchange Commission (the “SEC”). This amended registration statement is attached as a PDF.

On 22 July 2022, Alvotech filed a Registration Statement on Form F-1 (the “Preliminary Prospectus”) with the U.S. Securities and Exchange Commission (the “SEC”). This registration statement is attached as a PDF.

Prolia® and Xgeva® (denosumab) are indicated for the treatment of bone disease, with combined sales of nearly US$5.3 billion in 2021 AVT03 (denosumab) is the 4th product in Alvotech’s portfolio to...

On 14 July 2022, Alvotech filed a Registration Statement on Form F-1 (the “Preliminary Prospectus”) with the U.S. Securities and Exchange Commission (the “SEC”). This registration statement is attached as a PDF.

Four new members enhance independence and diversity of Board of Directors Alvotech (NASDAQ and First North Growth Market: ALVO), a global biotech company specialized in the development and...